Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 18/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165963 | 0.93 | PTPN1 (0.49) | PTPN1PTPN2 | |
| SCHEMBL5166237 | 0.89 | PTPN1 (0.50) | PTPN1PTPN2CNR2CA12CA1 | |
| SCHEMBL5165954 | 0.81 | PTPN1 (0.53) | PTPN1PTPN2CNR2 | |
| SCHEMBL5892036 | 0.80 | PTPN1 (0.60) | PTPN1PTPN2 | |
| SCHEMBL5167247 | 0.76 | PTPN1 (0.42) | PTPN1 | |
| SCHEMBL5165519 | 0.76 | PTPN1 (0.42) | PTPN1 | |
| SCHEMBL3732885 | 0.74 | PTPN1 (0.41) | PTPN1PTPN2 | |
| SCHEMBL3736018 | 0.73 | PTPN1 (0.39) | PTPN1PTPN2 | |
| SCHEMBL5166721 | 0.73 | PTPN1 (0.36) | PTPN1PTPN2 | |
| SCHEMBL3741682 | 0.73 | PTPN1 (0.41) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | PTPN1 2/4885PTPN2 12/4885CNR2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.